Quanta Inc (fka QNTA)

[falon]

Medofile Rx has the technology to outperform what VRML did back in 2009-2010 after getting FDA approval for a Ovarian cancer test.


Here is a message from this EPIC rise:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=41400873Sep 14, 2009 2.00 4.79 1.99 3.08 2,819,800 3.08

Date Open High Low Close Volume Adj Close*
Mar 3, 2010 30.00 31.56 29.05 31.50 141,600 31.50
Mar 2, 2010 31.25 31.43 29.50 30.20 113,000 30.20
Mar 1, 2010 32.00 32.70 30.55 31.43 157,700 31.43
Feb 26, 2010 31.00 32.24 31.00 32.03 133,900 32.03
Feb 25, 2010 30.20 31.25 29.05 31.00 124,300 31.00
Feb 24, 2010 28.70 30.25 28.60 30.00 194,000 30.00
Nov 13, 2009 22.70 23.53 22.30 23.20 328,900 23.20
Nov 12, 2009 19.25 23.70 18.80 22.20 896,300 22.20
Nov 11, 2009 18.00 18.95 17.75 18.75 36,000 18.75
Nov 10, 2009 18.60 19.00 17.75 18.25 48,200 18.25
Nov 9, 2009 17.40 19.20 17.40 18.75 119,100 18.75
Oct 14, 2009 15.10 16.00 15.10 15.80 297,400 15.80
Oct 13, 2009 14.65 15.79 13.26 15.25 150,500 15.25
Oct 12, 2009 10.26 14.75 10.25 14.65 396,900 14.65
Oct 9, 2009 11.25 12.00 9.56 10.26 604,600 10.26
Oct 8, 2009 14.80 15.25 12.50 12.50 219,200 12.50
Sep 14, 2009 2.00 4.79 1.99 3.08 2,819,800 3.08
Sep 11, 2009 0.05 1.29 0.05 1.29 1,942,500 1.29
Sep 10, 2009 0.05 0.05 0.05 0.05 1,700 0.05
Sep 9, 2009 0.05 0.05 0.04 0.05 1,700 0.05
Sep 8, 2009 0.04 0.04 0.04 0.04 18,500 0.04

Basically the FDA news sent the stock flying starting September 11, 2009 and it rose steadily until March 2010. It did hit the $20 range and October before retreating back to the teens and from there it did a steady rise to the $30 range by March 2010. With pull backs and consolidations along the way. The interesting part is the MMs did a wonderful job keeping a handle on this epic rise.

I believe Medofil Rx Future EPIC rise will GREATLY over shadow VRML’s rise.

Why?

Escozine and its many many solutions:

The Company assembled detailed information regarding the manufacturing of Escozine®, clarity on dosing, as well as both previous and new safety and efficacy data derived from an on-going human study taking place in the DR. The study has been conducted on over 500 participants and intends to demonstrate the safety and efficacy of Escozine®. Escozine® is a polarized solution of the Rhopalurus princeps scorpion peptide owned by Medolife, which has been filed with the FDA under the IND regulatory pathway as well as the Ministry of Health in the DR where the Company is seeking product registration. Previous clinical data was submitted to the FDA including preliminary results of the safety study, which has now been expanded upon. This data, as well as the batch of Escozine® that was produced specifically for the FDA, has now been submitted. After the review of the data and barring any further inquiries or requests, the FDA will designate IND status for Escozine®, essentially allowing the drug to be distributed in the US. After such designation, the Company will pursue other clinical applications of Escozine®, including as a potential cancer therapeutic where the Company has already released positive clinical results.

“The FDA-approved therapeutic drug market is the gold standard globally and should we receive IND designation from the FDA, it would catapult our other research across the world,” said Medolife CEO Dr. Arthur Mikaelian. “Submission to the FDA is never easy, but we are generating such positive clinical trial results that we are confident the regulatory body will take notice. They have been reviewing our submission for some time, requesting various other information that we have now submitted. I believe this could be the last request ahead of approval, which would be tremendous not only for our Company, but for patients who are in need of a solution where one does not currently exist. An approval from the FDA would also propel interest from the scientific community on the potential therapeutic benefits of the natural peptides we are studying, including investment and partnership interest.”


"The data proving the efficacy that Escozine has on a multitude of improved patient parameters is consistent with the rapid symptom relief I experienced while on site," said Dr. Annabelle Morgan, Cell and Developmental Biologist and one of Medolife's leading scientists. She noted, "What is even more astonishing is that 100% of patients tested negative for COVID-19 within 5-10 days of treatment."

"More importantly, all COVID-19 healthcare workers, including physicians and nurses, who took Escozine as a preventative, never tested positive" said Dr. Khalid Matalka, another leading scientist at Medolife, specializing in Cancer Therapy and Immunology. "The clinical trial results indicate that Escozine could be used as monotherapy or in combination with standard therapies against COVID-19, which will accelerate the healing from the virus. Besides, observations revealed that Escozine could be used as prevention from the COVID-19 infection."



Medolife has completed extensive pre-clinical and clinical research on Escozine® as a potential therapeutic for various types of cancer. After observing the research and reviewing the data, the esteemed doctor made a formal recommendation to begin use of Escozine® in cancer therapies. He came to the conclusion, as noted in his formal recommendation, after making clinical observations that patients who used Escozine® as a part of their cancer therapeutics regimen saw:

- Improvements in their quality of life

- Decreased intensity of pain in affected areas

- Decreases in the diameter of tumor masses

- Improvement in their sleep conditions

- Prolonged life span

- No observed side effects

The doctor also endorsed further clinical investigations on Escozine® as a cancer therapeutic, which Medolife is currently conducting in both the United States and the Dominican Republic. It recently announced pre-clinical results on Escozine’s efficacy in eliminating cell lines in ovarian and bladder cancer whereas it eradicated the cell lines completely, creating a path forward for Escozine® as a cancer-fighting drug, along with its life-improvement benefits.